146 related articles for article (PubMed ID: 38293753)
1. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract][Full Text] [Related]
3. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V; Aw A; Laferriere N; Abdel-Samad N; Peters A; Johnson NA; Bernard MP; Gopalakrishnan S; Bull SJ; Fournier PA; Klil-Drori AJ; Hay AE; Robinson S; Owen C
Leuk Lymphoma; 2024 May; 65(5):609-617. PubMed ID: 38235709
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
5. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
8. Pirtobrutinib
Al-Sawaf O; Jen MH; Hess LM; Zhang J; Goebel B; Pagel JM; Abhyankar S; Davids MS; Eyre TA
Haematologica; 2024 Jun; 109(6):1866-1873. PubMed ID: 38031799
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
[TBL] [Abstract][Full Text] [Related]
11. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Stilgenbauer S; Morschhauser F; Wendtner CM; Cartron G; Hallek M; Eichhorst B; Kozloff MF; Giever T; Lozanski G; Jiang Y; Huang H; Pignataro DS; Schary W; Humphrey K; Mobasher M; Salles G
Haematologica; 2021 Nov; 106(11):2834-2844. PubMed ID: 33121235
[TBL] [Abstract][Full Text] [Related]
13. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis.
Chavez JC; Grajales A; Sandoval-Sus J; Turba E; Nodzon L; Uriepero-Palma A; Ammad-Ud-Din M; Sahakian E; Komrokji R; Sokol L; Locke FL; Shah B; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Bello C; Pinilla-Ibarz J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):382-391.e2. PubMed ID: 38508880
[TBL] [Abstract][Full Text] [Related]
19. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
